Literature DB >> 26438531

Increased IL18 mRNA levels in peripheral artery disease and its association with triglyceride and LDL cholesterol levels: a pilot study.

Serkan Burc Deser1, Burcu Bayoglu2, Kazım Besirli3, Mujgan Cengiz2, Berk Arapi3, Yerik Junusbekov3, Ahmet Dirican4, Caner Arslan3.   

Abstract

Peripheral artery disease (PAD) typically refers to lower limb vessel ischemia caused by atherosclerotic stenosis of lower extremity arteries. IL18 is a pleiotropic pro-inflammatory cytokine reported to function as an inflammatory biomarker in cardiovascular diseases. IL18 activity is balanced by high-affinity naturally occurring IL18-binding protein (IL18BP). This study aimed to determine whether IL18, IL18 BP mRNA levels and -137 G/C (rs187238) polymorphism, which was previously associated with IL18 gene transcriptional activity, were associated with PAD etiology. IL18, IL18BP mRNA levels from peripheral blood mononuclear cells and -137 G/C (rs187238) polymorphism were determined by quantitative real-time polymerase chain reaction (qRT-PCR) and RT-PCR, respectively, in 55 PAD patients (26 aorta-iliac, 29 femoro-popliteal) and 61 disease-free controls. IL18 mRNA levels were increased in PAD patients compared with healthy controls (p = 0.09); however, did not reach a statistical significant level, also did not significantly differ between aorta-iliac and femoro-popliteal occlusive PAD subgroups (p = 0.285). However, IL18BP mRNA levels were significantly lower in PAD group compared with controls (p < 0.001). Genotype frequencies of rs187238 polymorphism did not significantly differ between PAD patients and controls (p = 0.385). IL18 mRNA levels were significantly correlated with triglycerides and LDL cholesterol levels in PAD patients (p = 0.003, p = 0.014, respectively). HDL cholesterol levels were negatively correlated with IL18 mRNA levels in controls (p = 0.05). This report is a preliminary study to show an association between IL18, IL18BP mRNA levels and PAD and suggests that the IL18 gene may have a significant relationship with triglyceride and LDL cholesterol levels in PAD patients.

Entities:  

Keywords:  Genetic polymorphism; IL18; IL18BP; Peripheral artery disease; mRNA levels

Mesh:

Substances:

Year:  2015        PMID: 26438531     DOI: 10.1007/s00380-015-0753-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  32 in total

1.  Interleukin-18 gene polymorphism and markers of subclinical atherosclerosis. The Cardiovascular Risk in Young Finns Study.

Authors:  Jussi A Hernesniemi; Arto Heikkilä; Olli T Raitakari; Mika Kähönen; Markus Juonala; Nina Hutri-Kähönen; Jukka Marniemi; Jorma Viikari; Terho Lehtimäki
Journal:  Ann Med       Date:  2010-04       Impact factor: 4.709

2.  Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation.

Authors:  V Giedraitis; B He; W X Huang; J Hillert
Journal:  J Neuroimmunol       Date:  2001-01-01       Impact factor: 3.478

Review 3.  Atherosclerosis.

Authors:  A J Lusis
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

4.  Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6.

Authors:  Johannes Hulthe; William McPheat; Ann Samnegård; Per Tornvall; Anders Hamsten; Per Eriksson
Journal:  Atherosclerosis       Date:  2006-01-06       Impact factor: 5.162

5.  Interleukin-18 promoter polymorphisms and risk of ischemic stroke.

Authors:  Na Zhang; Jin-Tai Yu; Nan-Nan Yu; Rui-Chun Lu; Teng Ma; Nai-Dong Wang; Dan Miao; Jing-Hui Song; Lan Tan
Journal:  Brain Res Bull       Date:  2010-01-25       Impact factor: 4.077

6.  Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

Authors:  Elizabeth Selvin; Thomas P Erlinger
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

7.  Promoter polymorphism of interleukin-18 in angiographically proven coronary artery disease.

Authors:  Wenwei Liu; Qizhu Tang; Hua Jiang; Xiangwu Ding; Yongsheng Liu; Rui Zhu; Yongqian Tang; Bin Li; Min Wei
Journal:  Angiology       Date:  2008-07-03       Impact factor: 3.619

Review 8.  Interleukin-18, more than a Th1 cytokine.

Authors:  Daniela Novick; Soohyun Kim; Gilles Kaplanski; Charles A Dinarello
Journal:  Semin Immunol       Date:  2013-11-22       Impact factor: 11.130

Review 9.  Interleukin 18 and coronary heart disease: prospective study and systematic review.

Authors:  Barbara J M H Jefferis; Olia Papacosta; Christopher G Owen; S Goya Wannamethee; Steve E Humphries; Mark Woodward; Lucy T Lennon; Andrew Thomson; Paul Welsh; Ann Rumley; Gordon D O Lowe; Peter H Whincup
Journal:  Atherosclerosis       Date:  2011-03-24       Impact factor: 5.162

Review 10.  IL-1β and IL-18: inflammatory markers or mediators of hypertension?

Authors:  S M Krishnan; C G Sobey; E Latz; A Mansell; G R Drummond
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

View more
  4 in total

Review 1.  The roles of interleukins in perfusion recovery after peripheral arterial disease.

Authors:  Lingdan Chen; Hanwei Liu; Mingjie Yuan; Wenju Lu; Jian Wang; Tao Wang
Journal:  Biosci Rep       Date:  2018-02-13       Impact factor: 3.840

Review 2.  The Discovery of Novel Genomic, Transcriptomic, and Proteomic Biomarkers in Cardiovascular and Peripheral Vascular Disease: The State of the Art.

Authors:  Stefano de Franciscis; Laurent Metzinger; Raffaele Serra
Journal:  Biomed Res Int       Date:  2016-05-19       Impact factor: 3.411

3.  Increased Expression of Interleukin-18 mRNA is Associated with Carotid Artery Stenosis

Authors:  Berk Arapi; Burcu Bayoğlu; Müjgan Cengiz; Ahmet Dirican; Serkan Burç Deser; Yerik Junusbekov; Caner Arslan
Journal:  Balkan Med J       Date:  2018-02-27       Impact factor: 2.021

4.  No association between interleukin-18 levels and risk of cardiovascular disease: A Mendelian randomization study.

Authors:  Siyu Fan; Pan He; Jieqiong Guan; Wenjing Song; Hong Zhi; Lina Wang
Journal:  Hereditas       Date:  2020-04-07       Impact factor: 3.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.